Recent studies have provided substantial evidence to highlight abnormalities in the structure of endometrial microvessels in users of progestogen-only contraception. Structural changes alone are unlikely to lead to breakthrough bleeding, but appear to be associated with a reduction in vessel integrity, and may reflect alterations in the control and growth of endometrial microvessels in those exposed to exogenous progestogens. In users of low-dose progestogens, immunohistochemical studies have demonstrated changes in superficial endometrial vascular morphology, density and in endometrial migratory cell populations. In Norplant users the endometrial endothelial basal lamina is deficient in the initial months of exposure, when bleeding problems are most common. The basal lamina refers to the very thin structure consisting mostly of collagen IV and laminin seen underlying endothelial and epithelial cells at the electron microscope level. In addition, hysteroscopic studies have demonstrated increased fragility of superficial vessels. Changes in endometrial microvascular anatomy associated with normal menstruation have been reviewed, and are compared with those seen following contraceptive steroid exposure. Likely mechanisms of breakthrough bleeding such as increased superficial vascular fragility and the possible alterations in endometrial vascular structure leading to this are discussed.
Introduction
Uterine bleeding requires the breakdown of endometrial blood vessels and the overlying epithelium. Bleeding that is irregular or prolonged suggests that the normal mechanisms which maintain tight control over vascular breakdown and repair have been disrupted. The depth of evidence implicating alterations in structure and function of endometrial microvessels in different types of abnormal endometrial bleeding has increased enormously since it was first seriously considered in 1979 (Fraser and Diczfalusy, 1980) . Bleeding that markedly differs in quantity, duration and appearance from normal menstrual bleeding suggests that different blood vessels may be the source. Circumstantial evidence suggests that endometrial capillaries and venules are the source of breakthrough bleeding (BTB). This is based upon the observations that spiral arteriole development is reduced under progestogenic influence, with more capillaries and venules seen (Hourihan et al, 1986 (Hourihan et al, , 1991 ; that progestogen-related bleeding is generally light and prolonged -suggesting a small vessel source (Fraser et al, 1996) ; and that small superficial vessels have been seen to bleed at hysteroscopy in users of progestogen-only contraception (Hickey et al, 1996a,b) .
The aims of this paper are to outline the structure of endometrial microvessels, to discuss how this structure is altered by exogenous sex steroids, particularly progestogens, and to relate these changes to the possible mechanism of BTB with these preparations. Normal anatomy of the endometrial vasculature Arterial blood reaches the uterus via the uterine and ovarian arteries. These vessels form the arcuate arteries in the myometrium (see figure 1 ). Radial arteries arise from the arcuate arteries at 90°t owards the endometrium. After crossing the endomyometrial junction, small basal arteries arise from the radial arteries and supply the basal endometrium and larger spiral arterioles which run towards the endometrial surface (functional layer). The spiral arterioles are thought to be sensitive to oestrogen and progesterone (Perrot-Applanat et al., 1988) , but the mechanism of sex steroid control of the endometrial microvasculature is less well understood.
Capillaries arising from the spiral arterioles form a subepithelial plexus which empties into a venous plexus within the functional layer. The spiral arterioles are thought to be acutely sensitive to oestrogen and progesterone, but the mechanism of sex steroid control of the endometrial microvasculature is poorly understood. These veins subsequently drain into the inner myometrium. Endometrial microvessels consist only of endothelial cells (EC) linked by tight junctions, their associated basal lamina and surrounding pericytes.
Endometrial endothelial basal lamina (BL) is a specialized form of extracellular matrix, which contributes to vessel growth, differentiation and vessel permeability. Vascular BL is a complex structure composed of several macromolecules, which interact to form the heterogeneous structure, which can be defined as BL. The BL also provides a sheet-like structure to which endothelial cells can closely attach (Bulletti et al., 1988) . Because BL is distributed across many cells, changes in its integrity or composition will modify the behaviour of other cell groups. Absence or disruption of the BL could thus contribute to endometrial vascular fragility and BTB.
Pericytes are associated with all vascular capillaries and post-capillary venules. Differences in pericyte morphology and distribution among vascular beds suggest tissue-specific functions. Pericytes may contribute towards the regulation of local blood flow, vessel formation and cellular differentiation (Hirschi and D'Amore, 1996) . Physical contact between endothelial cells and pericytes, mediated by cell adhesion molecules, integrins and gap junctions is likely to influence vascular function in the endometrium.
Endometrial lymphatics
The endometrial lymphatic system has been much less extensively studied than the vascular system. This is partly due to the technical difficulties involved in examining this system. Consequently, our understanding of the role and actions of the endometrial lymphatics is incomplete.
The work of Casley- Smith and Florey (1961) has been used as a basis for establishing the morphological criteria for the identification of lymphatic vessels as opposed to blood vessels. At the ultrastructural level, the lymphatic vessel wall appears substantially thinner than that of the corresponding sized blood vessels. The endothelial cells are less tightly attached and gaps sometimes exist between adjacent cells. The basal lamina of the lymphatic is mostly irregular and fragmented, and may be absent, whereas in blood vessels it is usually clearly demarcated. However, lymphatics may be difficult to differentiate, and the absence of erythrocytes within the vessel does not indicate that the vessel is a lymphatic. At the light microscope level, differences between these vessels are even more subtle and the lymphatic vessels may be seen to have substantially thinner endothelium. These similarities in appearance have obvious implications for studies of endometrial blood vessels. However, recent observations in mature nonpathological tissues have suggested that the VEGF receptor flt-4 may act as a lymphatic marker (Nojiri and Ohhashi, 1999) .
A detailed light microscopic, ultrastructural and three-dimensional study of the endometrial lymphatic system, in normal cycling women was performed by Blackwell and Fraser (1981) . This study showed that approximately two-thirds of normal human endometrium has a recognizable lymphatic system, with 1-20 vessels per square millimetre, mostly concentrated in the deeper portions of the tissue. There was no obvious correlation between the presence of lymphatics and the stage of the menstrual cycle, or the position of lymphatic vessels and that of other endometrial structures such as glands and blood vessels. Blackwell and Fraser (1981) suggest that endometrial lymphatics may play a role in endometrial regression seen preceding normal menstruation (Markee, 1950) and following sex steroid exposure, and in endometrial remodelling.
Endometrial vascular changes during the normal menstrual cycle
Most of the data describing the structure of endometrial microvessels is based on endometrial biopsy specimens and on in-vivo data from the 1940s by Markee using endometrial explants placed in the anterior chamber of the eye in the rhesus monkey and observed under the influence of oestrogen and progesterone. The physical location of the endometrium makes in-vivo studies difficult in the human, and it remains unclear how much information can be realistically extrapolated from non-human and biopsy studies. The late pre-ovulatory phase is accompanied by a 5-fold increase in the length of the spiral arterioles, leading to vascular coiling. Distal spiral arterioles connect to the sub-epithelial capillary plexus. During the secretory phase, the spiral arterioles increase in size and tortuosity, and the subepithelial capillaries dilate (Markee, 1940) .
Pre-menstrually, the endometrial stroma rapidly regresses and spiral arterioles coil. Menstrual bleeding is preceded by vascular stasis, vasoconstriction with brief relaxation of arterioles leading to bleeding (Markee, 1940; Christiaens et al., 1982) . Bleeding also occurs via gaps in vessel walls and epithelium, rupturing haematomata, diapedesis from capillaries and directly from endometrial veins.
Mechanisms of vascular breakdown
Menstruation is preceded by a fall in circulating progesterone and the activation of a range of local factors and mechanisms able to disturb small vessel structure and induce vascular breakdown. These factors include: (i) Prostaglandins (Cameron, 1991) ; (ii) Macrophages and other migratory leukocytes (Finn, 1986; Bulmer et al., 1987 Bulmer et al., , 1991 ; (iii) Plasminogen activators (Koh et al., 1992) ; (iv) Cytokines (Tabibzadeh and Sun, 1992) ; (v) Lysosomes (Henzl et al., 1972) ; (vi) Matrix metalloproteinases (MMP, Hampton and Salamonsen, 1994) ; and (vii) Apoptosis (Tabibzadeh et al., 1995) . Recent research has not been able to demonstrate close endometrial and vascular morphological correlations with specific abnormalities of menstrual bleeding, but has pointed to an increasing number of molecular mechanisms that may be involved in the occurrence of normal and abnormal uterine bleeding. These molecules have complex interactions, and the precise sequence of events culminating in endometrial vascular breakdown and repair is still under investigation. Endometrial destruction and regeneration are largely under the control of these local factors, although the initial trigger comes from falling oestradiol and progesterone concentrations following luteolysis. Lysosomes release hydrolytic enzymes in pre-menstrual endometrium that could contribute to tissue breakdown, bleeding, and remodelling. (Henzl et al., 1972; Christiaens et al., 1982) . Lysosomes activate in response to falling progesterone, but it is unclear whether they have a primary or secondary role in the onset of endometrial vascular breakdown (Fraser et al., 1996) . Increasing evidence suggests that certain matrix metalloproteinases are the agents responsible for extracellular matrix and vascular breakdown in normal, and perhaps also abnormal, menstrual bleeding (Hampton and Salamonsen, 1994; Vincent et al, 1999) . These enzymes may modify microvascular structure by removing supporting materials from the intercellular space and by damaging basal lamina.
Endometrial leukocytes are known to be involved in tissue destruction and regeneration/by the production of a range of molecules capable of damaging vessels as well as other tissue components. Menstruation is preceded by a marked increase in endometrial stromal granulated lymphocytes, T lymphocytes and macrophages. Polymorphonuclear leukocytes only appear in uterine tissues at the onset of tissue breakdown (Kamat and Issacson, 1987; Bulmer et al., 1988) and are often located near blood vessels in the endometrium where they may influence vascular permeability and integrity. This influx of leukocytes into the endometrium is clearly influenced by changes in ovarian sex steroid production, and small populations of these cells have varying oestrogen and/or progesterone receptor positivity (Tabibzadeh and Satyaswaroop, 1989) . The adhesion molecules intracellular adhesion molecule (ICAM)-l and vascular cell adhesion molecule (VCAM) are known to be involved in the migration of leukocytes from the circulation, through vessel walls and into the tissues (Lessey and Arnold, 1998; Searle et al., 1999) .
Evidence for the role of prostaglandins in the initiation of bleeding (Karim, 1983; Cameron et al., 1991) , and the control of endometrial blood flow (Einer-Jensen, 1973 ) has been substantial. Prostaglandins can cause premature bleeding when injected into the endometrial cavity in women (Toppozoda et al., 1980) , and induce bleeding in vitro in the hamster cheek explant (Abel et al., 1982) . Withdrawal of progesterone at the end of the menstrual cycle may promote increased prostaglandin production, producing the characteristic vasospasm that precedes vasodilatation (via prostaglandin F 2a ). This may also account for the common phenomenon of dysmenorrhoea during the initial days of menstrual bleeding. Prostaglandin release may further increase in response to the tissue destruction of endometrial ischaemia and necrosis (Smith, 1990 ) creating a positive feedback of vascular damage and endometrial breakdown.
Mechanism of haemostasis and vascular repair
In Markee's observations of endometrial explants, vasoconstriction of spiral arterioles limits blood loss in the early phase of normal menstruation.
Haemostatic plug formation occurs in the first 24 h, but these plugs are small, transient, intravascular and are rarely seen more than 20 h after the onset of menstruation (Christiaens et al., 1982) . In contrast to haemostatic mechanisms in other body tissues, menstrual blood does not show persistent clotting (Sixma and Webster, 1977) . There is early intravascular coagulation associated with major anticoagulation effects within the tissue and uterine lumen. Coagulation factors are reduced in menstrual blood, and there is greatly increased activity of thrombolytic endometrial tissue plasminogen activator (tPA) as well as plasmin and a 2 antiplasmin (Rees et al., 1985) . In collected menstrual blood, platelets are reduced and dysfunctional (Rees, 1990) , suggesting that the normal clotting mechanisms have been 'disabled' by menstrual fluid. In the late secretory and menstrual phase there are much reduced levels of von Willebrand factor (vWF), a substance which is crucial for platelet adherence to damaged vessels, suggesting impaired haemostasis . Endometrial repair commences during early menstruation (Christiaens et al., 1982) , and epithelial repair is complete by day 4-5 of menstruation (Ferenczy etal., 1979) . Angiogenesis is an essential component of endometrial renewal. The agents controlling endometrial angiogenesis are still under investigation, but this process appears to be con-trolled by a variety of angiogenic and antiangiogenic stimuli (Gargett et al, 1999) . Peptide and non-peptide angiogenic factors interact during endometrial renewal, including epidermal growth factor (EGF), transforming growth factors (e.g. TGF-P), platelet-derived epidermal growth factor (PD-EGF), tumour necrosis growth factors and vascular endothelial growth factor (VEGF; Smith, 1998) . These growth factors may act to control endometrial proliferation and differentiation. It is unclear whether the overall control of this process is mediated by oestrogen and progesterone, and recent evidence suggests that endometrial vascular growth may be largely locally determined (Rogers et al, 1998) .
VEGF is a fundamental regulator of normal and abnormal angiogenesis, and is necessary for cyclical endometrial blood vessel proliferation and in pathological angiogenesis in the female reproductive tract (see Ferrara, 1999 for review). VEGF is a secreted peptide, and the receptors for VEGF are localized predominantly on vascular endothelial cells (Millauer et al, 1993; Neufleld et al, 1994) . VEGF also acts to increase vascular permeability, which may be of importance in the degradation of the extracellular matrix during angiogenesis (Charnock-Jones et al, 1993) . Furthermore, VEGF also modulates the expression of a number of proteolytic enzymes involved in angiogenesis (Pepper et al, 1991) .
Changes in endometrial microvessels in
response to exogenous sex steroids The prevailing clinical interest in endometrial vascular changes in response to exogenous sex steroids arises from the common problem of irregular bleeding associated with steroid contraceptives and hormone replacement therapy. Alterations in the integrity of endothelial cells, their junctions or the surrounding basal lamina and pericytes could all compromise microvascular stability and promote vascular fragility.
Endothelial cell junctions
The role of tight junctions between adjacent endothelial cells in controlling endometrial bleeding is unclear. In decidua, endothelial cell tight junctions have not been noted to provide much strength in bonding adjacent cells together (Parr et al, 1986) .
Little is known about the role of endometrial tight junctions during the normal menstrual cycle. Adherens junctions appear to provide the bonding strength in epithelium, but these junctions are not present in endothelium. Ultrastructural studies have shown that patchy microvascular fragmentation accompanies menstruation, although in some areas vessels appear normal right into menstruation (Roberts et al, 1992) . However, there is little recent information on the ultrastructure of EC junctions following progestogen exposure (Blackwell and Fraser, 1988) . The identification of a marker for endometrial endothelial tight junctions might provide further information on changes in these junctions, and further ultrastructural studies are needed.
Exogenous sex steroids appear to influence vascular structure, growth and blood flow in the human endometrium, but accurate in-vivo work is hampered by the physical location of the endometrium and the size of superficial microvessels.
Long-term low-dose levonorgestrel leads to a reduction in endometrial arteriole numbers and size, and a change in vascular morphology with a decrease in arteriole spiralling, increased gaps between endothelial cells and haemostatic plugs (Hourihan et al, 1990 (Hourihan et al, , 1991 . Ultrastructural studies by Johannisson et al. (1982) observed contracted endothelial cells and an increase in plasmalemmal vesicles, implying a loss of microvascular integrity.
Endometrial microvascular density
During the normal menstrual cycle, endometrial vascular density does '• not significantly change, despite periodic angiogenesis (Shaw et al, 1981; Johannisson et al, 1982; Rogers et al, 1993; Grimwood et al, 1995; Song et al, 1995) . However, an increase in endometrial microvascular density has been observed following 3-12 months of exposure to the low-dose long-acting levonorgestrel contraceptive implant system, Norplant Hickey et al, 1999a) . In women exposed to high and medium dose progestogens a decrease in endometrial vascular density has been observed (Song et al, 1995) , while in those treated with danazol or the GnRH agonist, goserelin, or following the menopause, endometrial vascular density is constant (Hickey et al, 1996b) . It is difficult to reconcile these observations, but they suggest that some exogenous sex steroids, or different local steroid concentrations, may disrupt the normal tightly controlled relationship between the growth of endothelial cells and capillaries and that of surrounding glandular and cellular components of the endometrium.
The origin of this increased vascular density in Norplant implant users is unclear, and there is no evidence that low-dose levonorgestrel directly stimulates angiogenesis, as judged by changes in endothelial cell proliferation indices (Goodger and Rogers, 1994; Subakir et al, 1995) . However, superficial vessels with a neovascular appearance have frequently been seen at hysteroscopy in progestogen users (Hickey et al, 1996b) . It is possible that abnormal endometrial angiogenesis may occur by a different mechanism from that observed in other tissues. Endothelial cell proliferation is only one feature of angiogenesis, and the absence of increased endothelial cell proliferation indices does not mean that vascular growth is not occurring by other mechanisms. An increase in vascular density could also occur secondary to diminished programmed cell death (apoptosis).
Endometrial vascular basal lamina
A reduction in immunostaining for the endometrial basal lamina components collagen, laminin and heparan sulphate proteoglycan (HSPG) has been seen in the initial months of progestogen exposure, when bleeding problems are most common (Hickey et al., 1999b) . This finding was not confirmed in longer-term Norplant users (Palmer et al., 1996) .
Alterations in vascular basal lamina are known to contribute to vascular fragility in other organ systems. In diabetes mellitus there is a characteristic thickening of the BL, but with a loss of functional capacity and 'leakiness' leading to retinal vascular fragility (Martin et al., 1988) . In some tumours and inflammatory conditions characterised by vascular fragility the BL is absent or disrupted (Barsky et al, 1983) .
Basal lamina components may be reduced because they are not being formed or are being broken down. Recent data suggesting that MMP activity may be increased in Norplant endometrium (Vincent et al, 1999) , may account for this breakdown of the ECM.
Endometrial vascular morphology
Changed vessel morphology alone cannot account for bleeding, but it may be associated with altered vascular control and function following exogenous sex steroid exposure.
Dilated superficial endometrial vessels have been identified by several authors in endometrial biopsies from steroid-exposed endometrium (Maqueo, 1980; Hourihan et al, 1986; Song et al, 1995) . Dilated vessels that are superficial, thin-walled and with abnormal morphology may be more fragile. Using a hysteroscopic measurement technique, it has been established that mean superficial vascular diameter is greater in low dose progestogen users compared to regularly cycling women during the secretory phase of the menstrual cycle, and that there is a distinct phenomenon of dilated superficial vessels which bleed on contact (Hickey et al, 1998) . Preliminary three-dimensional studies using CD34 as a marker of endothelial cells have used image analysis to demonstrate the same dilated vessels join with normal sized capillaries and with solid columns of endothelial cells which do not appear to have a lumen. These findings suggest major disturbance of endometrial angiogenesis processes in the presence of continuous progestogen exposure.
In-vitro measurement of endometrial microvessels Apparent dilatation of the superficial endometrial vessels has been noted in biopsy specimens following oestrogen and progestogen exposure (Ober, 1970; Ludwig, 1990 ), but few authors have been able to provide precise measurements of these vessels. Peek et al measured the combined luminal and endothelial cell area in biopsies from the functional layer of the endometrium on days 20-22 in women with regular menstrual cycles who were not exposed to sex steroids (Peek et al, 1992) . The mean area of these vessels was 204 (im 2 , and the mean diameter 16.2 |im. Wide variations were observed between vessels. Following exposure to short-duration and high-dose oral levonorgestrel (0.75 mg; suitable for emergency contraception), there was no significant change in vascular diameter (mean 15.8 |im).
In-vivo measurement of endometrial microvessels It is difficult to assess vascular dilatation invitro since these vessels rapidly collapse. Using a hysteroscopic technique which corrects for image magnification and distortion, Hickey et al. found that mean superficial vascular diameter was greater in users of low-dose levonorgestrel contraceptive implants (Norplant) compared to women with spontaneous ovulatory menorrhagia (Hickey et al., 1998) . Vascular diameter was 120 ± 11.6 |im (mean ± SEM) compared to 74 ± 7.2 (im in those with menorrhagia. This study also confirmed the presence of scattered dilated vessels (up to 777 urn diameter) on the endometrial surface in some Norplant users.
The wide variation between these in-vitro and in-vivo measurements emphasizes the dynamic nature of vascular function and morphology, and the limitations of studies confined only to processed biopsy specimens.
Why are these vessels enlarged or dilated?
Because of aberrant angiogenesis ? The abnormal vascular morphology and increased microvascular density in progestogen-exposed endometrium strongly suggest that endometrial angiogenesis is disrupted by prolonged exposure to exogenous progestogens. The observation that growth of endometrial capillary endothelial cells exposed to levonorgestrel or 3-keto-desogestrel, but not progesterone or medroxyprogesterone acetate, in culture is markedly inhibited, may also be an indicator of impaired angiogenic mechanisms (Peek et al., 1995; Rodriguez-Manzaneque et al., 2000) .
Because of altered vascular perfusion ?
Preliminary studies using laser-Doppler to directly measure superficial endometrial vascular perfusion suggest that LNG from Norplant markedly reduces perfusion in some users (Hickey et al., 2000) . Vascular dilatation may be a reaction to reduced perfusion. Vasomotion describes the spontaneous and rhythmic dilation and constriction of microvessels. Normal vasomotion is profoundly altered by low-dose progestogens, with an almost total loss of short-term variability. Again, this implies that the control of endometrial vascular function is altered following exogenous sex steroid exposure.
As a direct effect of vasoactive mediators VEGF is expressed in the endometrium following progestogen exposure . VEGF can directly increase vascular permeability and may lead to dilatation. Hypoxia is a major stimulant of VEGF up-regulation. Changes in endometrial oxygenation are likely to accompany changes in vascular perfusion. Oxygen tension in superficial endometrial vessels or surrounding tissues has not yet been assessed. These effects may also be influenced by the local release of vasoconstrictor substances, such as endothelins, and lead to further alterations in local flow and dilatation.
Increased vascular fragility
Hysteroscopic studies in Norplant users have demonstrated a number of superficial vascular changes which are consistent with increased endometrial vascular fragility . These include: (i) Abnormal vascular morphology with arborization and mosaic patterns; (ii) Dilated vessels on the endometrial surface (see above); (iii) Contact bleeding from dilated vessels; (iv) Profuse subepithelial haemorrhages (petechiae and ecchymoses). These changes have not been observed in regularly cycling women who have not been exposed to sex steroid hormones (M. Hickey et al., unpublished data) .
Summary
There is growing evidence that structural changes in small and dilated endometrial microvessels are the source of BTB in progestogen-only users. Changes in these vessels may contribute to increased vascular fragility. These include increased vessel numbers, reduced vascular basal lamina components, altered vessel morphology with marked dilatation, and an influx of vasoactive factors and proteases promoting vascular breakdown.
However, few of these changes have been directly linked with bleeding episodes, suggesting that intermediate factors act between vessel breakdown and vaginal bleeding. Since the epithelium must also be breached before endometrial bleeding is seen by the patient, the role of epithelial integrity in containing bleeding from damaged vessels needs further investigation.
